Patients continue to be recruited into the phase 2 trial for DEP® docetaxel, with efficacy signals observed in a variety of tumour types including non-small cell lung cancer, prostate cancer, and several hard to treat tumours. Six sites in the UK are currently recruiting patients, including two new sites – the Christie and the Beatson (Glasgow).
We are still recruiting???
Can someone please correct me as I was under the impression that recruitment for DEP Docetaxel was finilised with expected data result readouts 1HCY20?
Ann: Quarterly Cashflow Report, page-8
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $41.73M | |||
| Open | High | Low | Value | Volume |
| 10.0¢ | 10.0¢ | 9.8¢ | $6.156K | 62.05K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 22787 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 199768 | 2 |
View Market Depth
| Last trade - 16.10pm 02/10/2024 (20 minute delay) ? |
| SPL (ASX) Chart |